RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.
Status:
Withdrawn
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Patients participating in this study will have a diagnosis of Chronic Myeloid Leukemia. This
study will evaluate whether the addition of an investigational drug called RAD001 given
together with Imatinib will better target leukemia stem cells, causing them to die. Stem
cells are a small population of cells, existing primarily within the bone marrow, and are
believed to be responsible for the ongoing risk of disease relapse.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center